Cerus Corporation (NASDAQ:CERS) announced today that the U.S. Food and
Drug Administration (FDA) has accepted Cerus’ clinical protocol to make
the INTERCEPT Blood System for platelets available under an Expanded
Access Investigational Device Exemption (IDE) to regions in the United
States with outbreaks of Chikungunya and dengue virus.
for U.S. FDA Accepts IDE Submission by Cerus Making the INTERCEPT Blood System Available to Address Chikungunya and Dengue Blood Safety Risks investment picks